AIMC Journal:
Expert opinion on biological therapy

INTRODUCTION: The molecular and architectural complexity of bispecific antibodies can introduce developability risks beyond those encountered with conventional monospecific antibodies. Therefore, whether developability should be integrated into the d...

BACKGROUND: Enfortumab vedotin (EV) has transformed treatment for advanced urothelial carcinoma (aUC), but outcomes vary. Machine learning (ML) with explainable artificial intelligence (XAI) may improve survival prediction. METHODS: Data from 544 aUC...

INTRODUCTION: Biologic therapies have transformed the management of moderate-to-severe psoriasis; however, long-term treatment requires optimization strategies to maintain efficacy, minimize adverse effects, and improve cost-effectiveness in real-wor...

INTRODUCTION: Biosimilar development is undergoing regulatory change, with growing emphasis on analytical comparability and targeted clinical pharmacology rather than routine comparative efficacy studies. A focused review is therefore needed to under...

INTRODUCTION: Biosimilar stewardship includes safety, appropriate use, and value. However, it faces challenges due to shortages in disproportionality methods. Artificial intelligence (AI) tools have been emerged as practical 'intelligence augmentatio...